Crossref
Subcutaneous lidocaine-hydroxypropyl-β-cyclodextrin for post-COVID condition
Ge-Bu · 2026 · e2026.1.1 (1) · 1
DOI: 10.35351/gebu.2026.1.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ge-Bu, 2026. Verfasst von S Biere-Rafi und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Biere-Rafi, S., Lafeber, M., & Bom, J. V. D. (2026). Subcutaneous lidocaine-hydroxypropyl-β-cyclodextrin for post-COVID condition. Ge-Bu, e2026.1.1(1), 1. https://doi.org/10.35351/gebu.2026.1.1
Vancouver
Biere-Rafi S, Lafeber M, Bom JVD. Subcutaneous lidocaine-hydroxypropyl-β-cyclodextrin for post-COVID condition. Ge-Bu. 2026;e2026.1.1(1):1. doi:10.35351/gebu.2026.1.1
BibTeX
@article{BiereRafi2026,
author = {Biere-Rafi, S and Lafeber, M and Bom, JG van der},
title = {Subcutaneous lidocaine-hydroxypropyl-β-cyclodextrin for post-COVID condition},
journal = {Ge-Bu},
year = {2026},
volume = {e2026.1.1},
number = {1},
pages = {1},
doi = {10.35351/gebu.2026.1.1}
}
EUVIMED